LOWELL, Mass., Nov. 26, 2018 /PRNewswire/ -- Alcyone Lifesciences, Inc., a leader in breakthrough technologies to treat complex oncolytic and neurological conditions through the company's proprietary advanced precision delivery platform, announced that the first patient was treated with DNAtrix's DNX-2440, an oncolytic adenovirus expressing OX40 ligand (OX40L) in a Phase 1 clinical trial for recurrent glioblastoma multiforme (GBM), a particularly lethal form of brain cancer. This also marks the beginning of a pioneering collaboration with Clinica Universidad de Navarra (Spain) and DNAtrix, Inc. (USA) for a treatment designed for adult patients with GBM combining DNAtrix's oncolytic virus immunotherapy delivered through Alcyone's Microtip Cannula Targeted Intratumoral Delivery System (AMC™).

The Navarra team, who is conducting the clinical trial, is led by neurosurgeon Dr. Ricardo Diez-Valle who commented, "The AMC System is a radically different and powerful therapy-enabling technology platform that allows surgeons to deliver the drug intratumorally, reflux-free, for controlled biodistribution. In addition, this device platform's dual channel allows us a simple real-time imaging option to verify delivery. We are thrilled to extend our collaboration with Alcyone and DNAtrix to test this important therapy. The unique combination of this novel OX40L armed virus with AMC is an important option to evaluate for patients with GBM."

"We are pleased to be collaborating with both DNAtrix and the Navarra team on this important clinical research for glioblastoma for the first time combining oncolytic virus immunotherapy to treat one of the most aggressive forms of brain cancer for which there is no cure," stated PJ Anand, Alcyone's chief executive officer. "Our AMC delivery system provides neurosurgeons with a reliable, repeatable and highly targeted intratumoral delivery system that is well proven and is also being used in our Phase 2 trial of DNX-2401 in combination with pembrolizumab (KEYTRUDA®)."

Alcyone and DNAtrix are in a multi-center intratumoral therapy collaboration with DNAtrix's first generation oncolytic virus DNX-2401 for the treatment of recurrent GBM. Clinica Universidad de Navarra also recently published a study protocol with the use of Alcyone's Microtip Cannula System for the treatment of DIPG (diffuse intrinsic pontine glioma) in the journal, Neurosurgery by neurosurgeon and Principal Investigator, Sonia Tejada, MD, PhD ( https://doi.org/10.1093/neuros/nyx507 ).

About Alcyone's Microtip Cannula (AMC™) Targeted Delivery System: AMC was developed using the company's proprietary microelectromechanical system (MEMS) technology platform. It has US FDA 510(k) clearance, Health Canada Licensing and CE Marking for specific targeted delivery applications in the brain. The microtip which has dual micro-channels, the AMC, features a unique patented distal end design that helps prevent reflux or back flow along the cannula shaft, which can be a significant drawback with current devices. The AMC platform device is designed for optimal targeted bio-distribution and neurosurgeon's ease of use. The AMC can be utilized with any existing commercial imaging and stereotactic system in conjunction with the work-flow friendly clinical use guideline designed by the company's scientist and neurosurgery advisors. Neurosurgeons can select a target, navigate the AMC precisely to the target, and observe in real-time the precision delivery of the therapeutic agent, all under intra-procedural MRI guidance.

About Alcyone Lifesciences, Inc. Alcyone Lifesciences, based in Lowell, Massachusetts, is a privately-held biotechnology company passionately committed to applying engineering and science in the field of neurosciences and oncology to enable transformative therapies. For more information, please visit www.alcyonels.com

Contact Alcyone Life Sciences, Inc. PJ Anand Chief Executive Officer 978-709-1946 info@alcyonels.com

SOURCE Alcyone Lifesciences, Inc.

For copyright information, check with the distributor of this item, PR Newswire.

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

PLEASE BE ADVISED: Soon we will no longer integrate with Facebook for story comments. The commenting option is not going away, however, readers will need to register for a FREE site account to continue sharing their thoughts and feedback on stories. If you already have an account (i.e. current subscribers, posting in obituary guestbooks, for submitting community events), you may use that login, otherwise, you will be prompted to create a new account.

Load comments